Novo Nordisk’s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus

September 21, 2010

Email this to someoneTweet about this on TwitterShare on Facebook0Share on Google+0Pin on Pinterest0

Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes.  The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD).
Additionally, Novo Nordisk presented phase 2 data which demonstrate insulin degludec’s potential to achieve glycemic control when used once-daily or three times weekly in people with type 2 diabetes.

For the full press release click here.

Email this to someoneTweet about this on TwitterShare on Facebook0Share on Google+0Pin on Pinterest0

Add a comment

Your email address will not be published. Required fields are marked *